(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 23 August 2007 (23.08.2007) PCT WO 2007/093409 A3 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K31/7088 (2006.01) kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, ClI, CN, (21) International Application Number: CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, H, PCT/EP2007/001294 GB, GD, GE, GIL GM, GI, HN, HR, HU, ID, IL, IN, IS, (22)JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, 14 In er a ioy Fiin Date: L, LU , LV, LY, M A , M D , M G , M K , M N , M W , M X , M Y, 14 Fbrury 007 14.2.207) MZ, NA, NG, NM, NO, NZ, OM, PG, PH, PL, PT, RO, RS, (25) Filing Language: English RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, IR, TI, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GIL 06002935.2 14 February 2006 (14.02.2006) EP GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 06024202.1 22 November 2006 (22.11.2006) EP ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): Er GB G E IS IL LU LV MC NI. PL PT NOXXON PHARMA AG [DE/DE]; Max-Dohm-Str. RB, SI, SK, I)S,AI (B, BJ, CE C, CI, CM, GA, 8-10,GN, GQ, GW, ML, MR, NE, SN, D, G). (72) Inventors; and (75) Inventors/Applicants (for US only): PURSCHKE, Published: Werner [DE/DE]; Wriezener Str. 30, 13359 Berlin (DE). with international search report JAROSCH, Florian [DE/DE]; Kiautschoustrasse 1, before the expiration of the time limit for amending the 13353 Berlin (DE). EULBERG, Dirk [DE/DE]; Schlie- claims and to be republished in the event of receipt of mannstr. 17, 10437 Berlin (DE). KLUSSMANN, Sven amendments [DE/DE]; Paulsborner Str. 83, 10709 Berlin (DE). BUCH NER, Klaus [DE/DE]; Assmannshauser Str. 3, 14197 (88) Date of publication of the international search report: Berlin (DE). MAASCH, Christian [DE/DE]; Emststr. 27, 13509 Berlin (DE). For two-letter codes and other abbreviations, refer to the "Guid (74) Agent: BOHMANN, Armin K.; Bohmann & Loosen, dance Notes on Codes andAbbreviations"appearing at the begin Nymphenburger Str. 1, 80335 Munich (DE). ning of each regular issue of the iCT Gazette. kn(54) Title: MCP-I BINDING NUCLEIC ACIDS (57) Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-I, selected from the group comprising type IA nucleic acids, type TBA nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to 115.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization International Bureau
(43) International Publication Date (10) International Publication Number 23 August 2007 (23.08.2007) PCT WO 2007/093409 A3
(51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K31/7088 (2006.01) kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, ClI, CN, (21) International Application Number: CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, H,
PCT/EP2007/001294 GB, GD, GE, GIL GM, GI, HN, HR, HU, ID, IL, IN, IS,
14 In er a ioy Fiin Date: L, LU , LV, LY, M A , M D , M G , M K , M N , M W , M X , M Y, 14 Fbrury 007 14.2.207) MZ, NA, NG, NM, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
(25) Filing Language: English RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, IR, TI, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
(26) Publication Language: English (84) Designated States (unless otherwise indicated, for every
(30) Priority Data: kind of regional protection available): ARIPO (BW, GIL 06002935.2 14 February 2006 (14.02.2006) EP GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 06024202.1 22 November 2006 (22.11.2006) EP ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
(71) Applicant (for all designated States except US): Er GB G E IS IL LU LV MC NI. PL PT NOXXON PHARMA AG [DE/DE]; Max-Dohm-Str. RB, SI, SK, I)S,AI (B, BJ, CE C, CI, CM, GA, 8-10,GN, GQ, GW, ML, MR, NE, SN, D, G).
(72) Inventors; and (75) Inventors/Applicants (for US only): PURSCHKE, Published:
Werner [DE/DE]; Wriezener Str. 30, 13359 Berlin (DE). with international search report JAROSCH, Florian [DE/DE]; Kiautschoustrasse 1, before the expiration of the time limit for amending the 13353 Berlin (DE). EULBERG, Dirk [DE/DE]; Schlie- claims and to be republished in the event of receipt of mannstr. 17, 10437 Berlin (DE). KLUSSMANN, Sven amendments [DE/DE]; Paulsborner Str. 83, 10709 Berlin (DE). BUCHNER, Klaus [DE/DE]; Assmannshauser Str. 3, 14197 (88) Date of publication of the international search report: Berlin (DE). MAASCH, Christian [DE/DE]; Emststr. 27, 13509 Berlin (DE).
For two-letter codes and other abbreviations, refer to the "Guid(74) Agent: BOHMANN, Armin K.; Bohmann & Loosen, dance Notes on Codes andAbbreviations" appearing at the begin
Nymphenburger Str. 1, 80335 Munich (DE). ning of each regular issue of the iCT Gazette.
kn(54) Title: MCP-I BINDING NUCLEIC ACIDS
(57) Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-I, selected from the group comprising type IA nucleic acids, type TBA nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to 115.
WO 2007/093409 PCT/EP2007/001294
MCP-l binding nucleic acids
The present invention is related to nucleic acids binding to MCP-1, and the use thereof for the
manufacture of a medicament and a diagnostic agent, respectively.
Human MCP-1 (monocyte chemoattractant protein-1; alternative names, MCAF [monocyte
chemoattracting and activating factor]; CCL2; SMC-CF [smooth muscle cell-colony simulating
04 a4H P 04 04 04 04 (/2 04 a 4 Z ) m ) U u~ U U U U04 u 01 U I r
N4 4 N4 p :1. 04 01 v Cl) 02> Cl) Cl) Cl) E- Cl ) U H U U ZD U u U U Cl) )Z ClU) l) Cl) C)H p Cl) 4 Z (9 9 9( ( 01 (9 H- "H4 H > > UC2HC) H- U U U U U U U
IY UC) :4~ C4 Z4 ly 0 H H < <:1 <~ < < < >-I >UCl >I >4 >-I >4H >I 1:4 >4 (9(9(9(9(9(9(9 Cl) U)Q Cl ) Cl) Cl) )H Cl) Q CO) U U U U U U U
0 )~ 0 01 01 H 01 i 01 a (9(9(9(9(9(9(9 > xH > x H- >H p 4 Hy (99((99(( C/) a4 Cl) C/) Cl) Cl) ) 04 01 a4 ( ( ( ( ( ( (
" 44~ H H- H>- H i F ( ( (9 9 9( ( 4~ ~ ~ H 4 4 S l ) 4 0W 0 ((9(D9(9(9(9(9
Z C12 p ClU) z z Z U U4 U U U u u nU HHH0P 4 PHa4 E- 4 p p H 4 o Ha4 (D (9 (9 (9 (9 (9 <~
4 t ) ~ t i rX C4X4X r4 4 Z > 4(D (9 (9 (9 U( (9 Z i4) U) Z 04Hp04HP0aH04 D 4 a4 Z~ 4 :) = >4Hp>4 0 >4Hp>4Hp>1 p>4Hp >H~-( (9 (9 (9 (9(9(
UHU-4 U uH u zuw u x UHPCI-4ipU r-i (9 (9C (9 (9 (D (D H01H PZ p YPxpxp4 P X0HH H U 4 P H (9 ( (9 (9 (9 (9 (9 > x F 1: > x> 4> x>~ H4F- XUl) "0 U U U U U U U
*0400) 4012 0400 4 00401)040C U) 0H04 0U U U U U U U < - 4)~ P H HH -u u u U U U U
0 U) 0Cl) p0C) UC ) 0 > 44<40 /U U C U U U U U ai 00a4HP> 0a4 C)0 W0 04 0 a4 0004( (9 (9 (9 (9 (9 (
~ *H -H -H H H - H * V ) a) a) a) ) a) a) 0) )
-P -P 4J 4- P 4J 4 14- 4J 41 ~ z- z z Z z z 0 0 0 0 0 0 0 0 0 1:4 1:4 W- z
LO %-I N- 00) 0 C) i-A N Mr qr Lo) o V-
WO 2007/093409 PCT/EP2007/001294
U
O 0 a O O i-I CN C14 rI N 0 l | Ln $4 U U U 5- U U C- C) C) 00 r-A r M y Q 4.1 5-1 5-I 5 4-I P4 P 4-) 4-W 4-) 4-) 5I 0 0D 0 0D 0D C) 0 0D
C) 4- 4~J 4-J 0) 4-3 4J -i ' - A C)4 0 CD -) 1 1 1 1 1 1 1 1
I I I I I I I i i i i I r i I I I I I I m~~~~~ ~ o o1 o1 ol o ol o1 . . DC )C DC )C
(D < 0 (D D uD D D D D n u 0 u u u D u 4 O O O D u O 0 0 < 0 < < < 4 4 4 U < U U U Zr U G U n U U U 4 n D 4 U U 0 0 0 0 O S 0 0 U 4 4U < < U U U U U
DDD ID u D n D D n u u
0 0 D D 0 D D 0 0 0 D 0 D u :D u u u 0 D n n D D 0 0 00 0 0
< < 0 4 0 D D D 0 0 00 00 U KC < < < < < 0 0 O 0 0 0 n n
4 < < < < < U U U U 0 U U U 0 U D 0 0 < < < < < <04 U U 0 0
000 u u 0 0 00 0 0 u u 0 0000 0
u O O O O O 0 0 0 0 0 0 D D D ZD G
00000000000 0 00 0 0 0 00n
G GG GG GG GG GG D u u 0 < D Z 0 U 00 0
000 < F < < U U 0 U 0 U U 00 00 00 0 0 0 0 Kc 0 < ~ 1 u
n D : 0 0 0 0 0 0 D D D: < LD < U U
0 U u u D D n =) u u u u u u n D 0 0 0 0 0 4 D D u u D u n O u
U U U U U < 4 < < < < <:: U U U U U U U U
0 0 D 0 04 0 0 0 4< 0 u 00 0 0 0000 00 0 0UUUU U<< 0 0 0 0 u D D D n n 0 0 < 0 < 0 u
0 00 00 0 0 000 0 000
< < < 4 K4 < < < F: < < U U
OOOO< < < < < < < <
r- m m CD O- m O w O O W - m m CD D- m ID L O w
000000 O O O 000000 D D C GG GG 000000 G U V 00
0000000000 D D D D 000000 & V 000000000000000 C O O 0 O 0 00000U D D 00000000A U
0)000000000000 GG G U O 0 U 000 0000000000000000000 4 4 < O
z 000000000000000 z z z 0 z 00z I) i i i 1 0 I 0 0 0
00A 0 0 0 0 0 0
O 0 0e~00 0~0~0
,W 2007/093409 PCT/EP2007/0012 4
x 0 z
oC r- C
rX) - w r to r- Lo [r- cN c,4 t w Ln (N I LO Lo
I I I I I I I I I I I I I I i I I I I I CO w o o o 0 o o o 00 0 o H H H- 1- o m o H 0 o o co
o U Co a) ) O a) a CO CO l i- O- CO a) a O O a) C
OD r- r- r- r- r- r- r- r- r- 00 00 OD r- r- r- 00 ir- r- i
U U U U U U U U U U u U
:D O<< < 0 4 4 4 4 4 4 4 u u
(9(9(9 U U U U U e U U U U U U U U U
DD m D
(9(9(9O U U U U U (9 U U U U U U U G U (9
U (9(9(9 U U U U U D U U U U U U U U (9 U (9 D D (9(9(9(9(9 4 (9(9(9(9(9(9(9 U U U
D 4u
S U U U D U U U U 4 D (9 (9(9(9(9(9(9 U (9 U (9 U (9(9(9(9(9 U D U
D 4 4 (9(9(9(9(9(9(9(9(9(9(9(9(9(9 U (9 (9 U U U (9 < < ) < D D) < D (9(9(9 U =) < D U U U U U U U U U U U U ( ( D U < < < u < < < < < < < < < < < U u U
< U D U U D U U U U U (9 4 (9
U UU D U 4U U
0 C D 0
(9 U U U U U U U4 vC U 4 4 4 O 4U U4 4 4 4 U U U
U) n t: : D D 0 ZD 0 0 ZD n D n n n
D D n D : D D: D: rD :D D:: D: :D :D ZD n n n D D
u D n n n D D ZD n D :D D 4 0 4
U U
m m W O 4 O - w 11 IV O -O w IV O O O n LO L O LO G O
(9 GGGG GGGU U (9 DDDDDDD
(9(9 GGGGG GGGGG
(9 | | | | | | |
U U o(9(9(9 H M M) (9 m o99( oD O (9 M 0
U 99999999((((((((
WO 2007/093409 PCT/EP2007/001294
C'J 6z 10 'k r- oo Hi "\ Lo 'D r- oo m' c0 -i (\.J m CD C0 42 C) 0) CD 0D ni H- H- Hl H C14 (N (N (N U U
Co (Do 4 Co Co Co Co Co Co Co Co Co Co Co Co Co Co Co Co Co Co
1- H- -- H- H- H H H H H- H H- H H H- H- H- HW Hw H
000 D0 0O Dc o0 00 o0 000 00 00 0000
u9 u u1 0(99 <J <0:4uuu
09( 000 0 00 u (9 u 0 u0(9uuu
0064 0 00(( 0(9(9(<990 n
(90 0000 000 00u00( (9u
n (9 (999((( 0 0 (9 0 0 iI 0 0 0
(9 000000n:):):)D 0 0 ) D (9(9(90
u U U0 00 U(9(9000 0000
L) U u u u u rOID (9
u 000000:) ) u 0 ) (99( <0 < <<<<
(9u u) :) ) :) : u) (99(n (9(9(9(9(9(9(9(9
Ui (9 (9(9(9(9(9(9:1: (9 U<
(9 KC000<((9(<(9(<9n(9U
:' u 0 u) (009 0: (9 u (9 iu1 :) (9(9(9u 0 u(9(n9 nu 1/((: (99( ( 9990 0 00 u u
n 0 u u u u u 0 < 0 u < n u 0 u
r- 00 m' 0D H- (N m I- 10 w r- Co m' 0) H CN m? w 10 w 101 10 "0 w 0 "D w 0 w " w 0 w 0 "0 "D - r ~~ - [- r
WO 2007/093409 PCT/EP2007/0012 4
-NN |l | | |n
~~0 0 0 0D 0)c o- o- o- 'a o o o- o- o- o- o4 4 4 CD C 44 4 4 4
<
CD O- O- r- k.D 0- 0- 0- O- O- r- r- r- r- r- r- r- r- r- rCo CO C r-I H ~ Co- Coro-oA r- r- r- r- r- r- 1-A r-4 i-i H >
U Ou <
C D u U u n
D C D CD4 D M < O U n D 4 D <D 4 :D CD =) = 0 C CD C CD
G O C <D CD C)CD)D C) <
G ~ ~ ~ ~ L 4 => U F: < u u 4 u D u <
< < D C UD (D (D C 4 D (D
C) C) L) 0
< CD u u D 4 4 DU :D :)DCD D < CD 4
CD C D C) CD C) U < n < n
C) CD CD C) G O C OD D
=> C) <)C
CD = CDO C C C D 4 C
D C C) D C) C) < u C D C Z D C C)D C C F C CD
4D 0 0 F: 4O4 4 <O gA CD CD 4 C4D C D C v D D
CD CD CD CD 0 D D 4) 4 4 O C C I CD 0 U Z u 4 D4
D D M CD 4 CD C C) CD CD CD CD CD CD) CD L) C) C CD CD D C CD C D 4 C C )
CDG D C )DGG C) CD GC C) D D D C D C C C C D CD C n D < <
0 D (D 0 0 0 0 0 0 0 0 u D 0 0 O 0 0 SD D D C CD C C C C D :) I D< 4 D U
< F:44 F: < D 0 n 0 0 u 0 0 u u F4 C D U CD: CD: CD 4 D n D u D
D D n 0 4 C 4 4 C C 0 < 0 D U 0 0 0 0 0 n < D 4 D 4 :4 D C4 < CDD < CD D D 0 D 0 D < D C 0 n CD 0 C C C C C D D C ) D C) C C C C C C) SC U ) D CD C C D
En U U C) CD C) D C CD CD D D CD CD CD CD C
z z z -z z z z z z z z z z z z z z z z z I I I | I | I | I I I | | | I I | I |
r- o c CD H N M IW LO ' r- o M Co a N M LO ko o o o o o o o o Co O O O O
WO 2007/093409 PCT/EP2007/0012 4
u o o) u u o u u u u o u o u o o u o u o 4J 4J 4J 4J 4J .) 40 . 0 ) - 4- 40 40 40 40 40 40 40 40 0
IV (N (N (N m C 'j ( N J mN H ~ r - r- LO r- w O w r - '.0 Cr)
O r- wr 00 0 w w w OD ~oD w w OD 00 m 0 m x S a r a Co Co O Co O o Co Co o o Co O
0 U U U U U U C 0 U uU C 0
< < < < < < < u u (D U U U U U U U e U 4D U U U
G U O O CDV U U < U CD CD U U C4 CD U U CD CD CD 4 U CD CD: CD U U U U U U U < U U U U CD U U CD CD U D C L OD D D U C D CDU
D C CD CD C UD C U U U ) ) ) C D CD m DD C CD u uD C U U U U UD D SCD D U DD D C D O C C) )
CD 4 CD U U CD CD D < O UD U U U U U U U 0 U 4 4 CD CD < < CD
L D D U U 4 D U 4 C Q D CD U = u U u D u UD U < 0 0 D D n (DG U u u 0 A 4 < 4 4 4 4 < < < 0 (D 0 (D Dz D M n < u n < u 0 0 4D (D < 4n U C D D n D D D U U D < < 0 D
D u 1 D 0 D 0 n n 4 n D ) u 0 D D D 4 D D O (D 4 4 0 u < < O D D 4 4 D Q D (D 0 (D D C9 D u m D 0 < (D Z:)
D 0 u U 9 D < 4 < 0 4 < u < CD C D < < U M CD D CDD ) C D u n U
C U U CD D D D C D C C U U D u (D < D D D 4 U 0 4 0 <D u D
4 U U U U < D U:):) < ) < U CD U U C 0 < 4D u C D U Q D U
nn U< L < 4 D < D C D 0 < D n CD C DV 0 C :) D D CD < C D C D
u C C C 4 D C C C CDV U U C C C D u 0 D O< < u 4 4 u n 0 < D < u G u
0 u 0 0 u u 0 D 4 D 0 < < 0 < u D cu 4 U u u u D 4 U u
D 4 u 0 n D 0 0 D 0 0 <
u ) ) u :) 0 D u CD:) D U U U C SCD D CD D D D D D 4 U D CD C C C C a
U U U U W U U U U U C C C 4 4 4 I LO
z z z z z z z z z z z z z z z z z z z z
H
-- Co 0 CO I a N m I LO w r- o 0 O H (N m I LO 11 CD e C 0 O O 0 0 O 0 0 C rA H H a aI H
WO 2007/093409 PCT/EP2007/001294
0 : z 0
0 A E C|| 11'O'
H ; LO w 6 r- rH N m - m CD N -P C C- oD L D o [o C) Co C o o ) o C ( i - ) o o o o o ' a o o o o o oI o H H m U
S I I I I I I I I I I I I >lrH- >: H1 4 4J
W ~~ 4 4 44 4 r4 U aoOD OD 00 OD 0 0 OND 0 )00 0 0 Hl - 04 l CY) I I I I I I | | I | | | | | JC 4 ) u I I I
x o, o o, o, e a, on on o-n a- o, on o~ 0 z on on on Oo o a, a, a, a, a, a, a, a, a, a, a, -H 1 - I e 'o e z H H H H - H H H H H H H H ,QQ ,Q Q H H
Z OD 4 H a>
u n0 0
U < < < < 0 C D n C> 0 C) n :
u0 00 00( 0 0> u D 0 0D < 0 G0 u u i M C C U U U U O < U U 0 U F- 0 0
a U 0 0 C) O 4 C C C C) > u u u U U U < U U 000 H > 0 < u C) ) C) C) C) C) 0 C)I C) C)u
I 4 0 D D > > 0 4 0 n o eD GG < < U : D
u 4D 0 D DD 0 0 w w
) ) 0 0 0 n) 0 0 n 0 0 C C D 4 1 00 D 0 00 n ) C) 00 C) ZD 0 n 0 0 U) e ) C) 00 C) C) C) D DOG D D ml ol 00o 00 C D n 00 n 0 00 H-4 H M D D
S0 C C C 00 n n 0 0 -I C) C D 00 C) C D n 0 D D G ::) C) H u C) C) C) C) C) D D G D D E O u < u U D D n D n D: D: 4
C 0000 00 D n 00 D n >q 00 0 00 C 00 0 0 0 n F:: < 0 0 C) Cf) C) C) C) G 0 < < < < D < < < w (D 0 00 4 < < < 4 0 F-4 4-4 C) C) C)
D 0 =O n 0 D r1 CD 0 0 C n 0 0 00 DD 0 0 > x -10 00
* 4 4 4 4 < u n u u 0 0 m a -P0 00 C 0 0 A U 0 D C) 00 U 0( C00 u0 0 n 0 n u C) 0 n C) C) 00 U 0
< u 0 C ) 0 C) 000 C C CI)IC) C) C 00 00 000 0000 x ~ -L1 00u
n D 0 0 0 0 u 0 0 00 0 F E G a (D (D (D
C)DC D 00 00 0 0 4 CH "O 0 < : D < u Y U < < < O
U ODD OO 0 U E--> M a 0 U (D ~ 0 0 C) 0 u C)C 0 0 Hp HYPZ 0 0
U C D U U 4 C C) 0 C C C C) C U C i < < 0 D < C C) < 1 < F4 U C) U D a U D Z 4 D u r m C z :r: C z z C) c) U D < < ) 0 C ) 0 C u O -,IH -- I > 0D 0 0 ( 0 ( 0 D 000 C ) -P 40-H < D <C D 0 L D U U C 0 o 0 u o 0 00 C) 0 0 U 0 4 C C 0' U C) 0 C ) Q -A 00 0 -Q A 04 C) C) 000 0 00 C) a 000 Coomoo
KC ~ ~ <C W a Z Z Z Z Z Z Z Z Z Z Z Z Z 4J 4 z z z
R R R M o 0 0 z
5- I I 04 4 004
H o , O 0 I N ) t L r - O 0 0 H N m T
r-I - N N N N N N N N N N m m m m m
WO 2007/093409 PCT/EP2007/001294
u 0 U U. -I U $-i
4J 4J CN -P CD 4m 0i O m
I I I I I o.3 03 mo w
D CD C M (9 (
4F: <
u ( u u D
L ( L ( u
u u ( u 9
(9(9(9(90
) ( 0 ( 9 u u u u u
ZD 4 D D D
(99 u (9( F94 < <99 ( 9 z ( 9 ( w(U((9( (9 m ( 9 9 r99 (9 (
(9(9(9(9(9 (9(9(9(9(9 (9(9(9(9(9 (9(9(9(9(9
(9(9 (9(9 (9(9(9 (9
LO O & D 0 r-) r- -
WO 2007/093409 PCT/EP2007/001294
0 o u u u o - o l- o N o u U U U U 0 -4 4 ) CD C o o ' 4 -I I -P 4) $I ~-P 4 J) - P 4J $i 0 0 0 0 ( C
4 4 (D 4 4 H H C C 4 I I I I
r- (~ D ' D W L) Wf n WI 0 0C0O 'W t- 1- %D W W -O W W D D ) 4 a a 9 o e o r-eo e o o o o
D r
G CD C CD U D D U D
D u < m < m u
U U U U U : U U U U C CD CD n n n D 4 4 U <<D n UU M
U
D
C C C 4 D n D D D D u u u C
U < U U U U U U CDU D D D CD C 4 4 4 U 0 U U U U U C C C u u u D
CD C CD CD C U U U U U CD D C
CD C D C D C D CD CD CD CD su
CD CD CD CD CD CD CD C CD CD CD CD CD CD
u u u u < < < < < < < uuuu
U U U CD CD CD CD CD CD CD CD CD
n D
u u u u C D D C CD C D 0 <
CD CD CD CD U U U U U e e U U U U CD CD CD CD CD CD CD CD CD CD U U U
SD CD CD CD C CD CD CD CD CD CD U U U O
< D D D C
G GDC CD CD CD CD CD O CD CD U U U U
~z z z z z z z z z z z z z z
H CD H O w 4 4 4 4) 4 N m 'w
lw w O lw -V O 4 11 I- w OO O LO O LO
6 U) GGGGGG
WO 2007/093409 PCT/EP2002/001294
C O C )O I k
Q4 Q - 4m< U
CD CD CD o) 1 O o0 oD o o oD o o0 o o -- -- -1 o0 o
4~o o o o I
00 co O op Z r- r- r- r- r- r - r - O D c - r
U U U <<<<<( : u U O U < U U u u
G G (9(9(9(9(9 U (9(9(99(9 (9(9( U U U U U (9 U U U U U (99 < <9<9<9< ( < < < < <
:D 0 0 0 0 < 0 0 0 0 0
0 u u (D u u D 4 u : u 0 u n u u u (9 U U (9 U U U U U U (9 U U U U ) U (9( U (9(9( U U U U U U U U U U
U (D (9 D D D (9(9(9(9( n (9(9(9(9(
u O m D u 0 n U U D :D 4 U U U O (9(9
(9(9(9(9G U U U U U U U U U U U U U (9(9 D (9 (9(9(9(9(9(9 U (9 U (9 U (9(9(9 U D (9(9 D 4 9(9(9(9(9(9 (9(9(9(9(9
u u u r) (9 u u )
U (9(9 U U U U
U (9 U U (9 UOOOO
G G U U G D D D D) D =)= U U = U (9(9(9(9(9(9(9(9(9 (9(9(9(9(9 U U U )O (( (9(9O O )
U U U U D D D D 9 D9((9((9((D((9D
U (9 U U U U U U U U U U U U U U U U S< 4 D D D
UDUUD < < < < uu< < < < < <
Su r CD n n n n D D (N m :D n D n D
If) U D D Lii O O W 0 O C-- [
< A u u u (D D D D DI u u < < u O O O O O OOOO
: < u u < U D D rD n n D D n
:: < U U U U U U U U u u u u
I v-I vIv-| |- - | v- | |- v-- v v- v-- v | |
U D 0 0 , 0 0 0 O 0 0 O O 0 0 0 O
<A
u~ u < < u U U U o U o L
WO 2007/093409 PCT/EP200 /001294
o r- C N in O r- o -i N Lo o r o o
(N 1 N 1 1 1 1 0 1 1 1 -1 1- 1~ 1~ i1 1- 1H 1 I I I I I I I | | I I | | | I | I
in Ln Ln Ln (N (N (N (N (N N (N (N N N N N (N N
- 4 QI
u u
<FC0UUUU U< U U U
U U < U U L < < < U 0 0 U A u 0 0 u 0 u u u u 0 0 < 4 < u u u u O 0
00 0 000 u u 0 0 0 0 1 0 4 u D u 0 0 0 0 00 0 0 0 u 0
0 000 U 0 0 U 0 0 U U U U U U U U 0 0 < 0 < 0 0 00 U U U0 U U
00 u 0 u 000 0 00 00 'u 0 u 00 G n Z n n 00 00 n 00 < u u u U u u D n D u =) n
S < < < < < < < < u u u u D u
U 0 U U 0 0 0 0 0 0 0 < 4 0 4 4 0 u 00 u u u u 0 00 u 0 0
0 0 04 00 u 0 u
n 4 0 < < 0 0 u 0 0 0 0 0 0 0 u u u U D < :D D D < < < 4 4 U U4 U U
D nD D D n < < < < < < G < <
D~~~~~~~~ D F:4 GGGGGG
n 0 u 0 0 u u 0 00 u 0 0 0 0 0 0 0 u D D D < < 0 4
u D D 0 u D OOGGUD 0 < 0
0~ 00u
~z z z z z z z z z z z z z z z z z z z Q QQ QQ Q Q z z z
o o o co o ca N m e 0 0 o N
H 0 %.0 r- 00 m 0 r-I N m V in w r- m m 0 H N C- I-i r-4 r-4 r-I - C--i aA aI a) H) H) a H) H) H) a H~ H
4)
WO 2007/093409 PCT/EP200"/001294
o 0 0 o 0 O 0 0 0 0
t-1 (N m V (N I I I I I 4 (N (N (N 0 o u o 0 0 0 0 o u u 0 0
i 0 0 0 $- $ N S- S- 5- S i 0 0 Si S- Si C A D W n I4 n in in C) D i4 O4 ( N
I I I | 4 4 | I 4I II I I I 4 4 4 I
m o o o o o o o - o o o o o r- r- r- r
0 u u
(9 u r: u (9C9(9 u u
u u (99( u u u u D 9 u u
uu u u 99(( u 0 (9 L : 0~~~ u 0(0(()
< 000 U U U (9 0 ( (99( < ~0 0(9 u
(D~~~ (D 0 <
0 u u U U0( D
GD ( U 0
000 ) r) D n ( D u 0
< 0 6% U U OD O D DD O D
m 0 n 4 4 4 < u O n u~ ~ 4 4 D m u 0 n m 4 D Du:
(99(((99((0 u (90
G~~~~ n n 4 OGDO O n 0 F: n n Z O<O 4
( D 9 ( ( (99(( D n ( u 49( u ( u
0 0 0 u u < u u u 0 D
0 )09(9(9(9(9(00( (9 0 n 0 00
~z z z z z z z z z z z z z z z z z z z z
0 ~~ () 00 0 0 z 0 0 0 z z z z
00 0 0n 0
r-I H r- H - H 1 ~ ( N ( N ( N N N (N (N (N (N (N
a, GGGG Ci) DDDG G
WO 2007/093409 PCT/EP200"/001294
N CN N 4N M 4N N C < N m ( CN r- r- LO r
I I I I I I I I I I I I I I I I I I
W r- n- u C0 0. '.<0 C< u. '0 '0
U U U U U U 0 U U U U U U 00
U UD < 0:: 0 U : ni U 00 U U U n U 00 U
: D 00 < U 00 U U 0 O 00 U 00 4 G G OO OO O O U U U U
0 < 0 < D n u U 0 n u 0 0D < 0 m U D D 0 u n u
000 U 0 0 0 0 U U 0 0 n 0 ~~ 0 U D 4
4 u 0 u 00
< < 0 u u 0 n 0 D 0 0 u u u u 4 u 0 D D : DG
D U 0 0 < u 0 0 D U 0 u 4 0 4 0 U 00 4 U 0 < 0 U
0 D D < u 0 < < u
SD O :D U U D D < U U 4 e U
D (D 0 < u u u u 0 D
0 0 0 u U 0 U U 0 < U
00 uU 0
U U 4 DUUD GD 0 4 U 0D U D
SD U UU U 0 G U 0 4 D
u u 0 u UO 0 0 0 U 0 U 0 u u u U U ) 0
0D U 00 U 0 u 0 U 0 U U 00 U U 0 C
O 4 e o e U G GU 4 0
00 D D 0 G D U U D 0 e U 00 e ~U G<U U U U U 000000 U U UD
4 4 0000 U U4 U U U U U U U 00
H o r- O m ) r- 4 ( 4 ( ' Le 'o O mH (N 1. -I H r1 A H H H .- A '] C. (N C. '] C. '] . (N (N m (Y Y
(N N N N N N N ( ( C.] C'] N N (N (N (N N (N (N (N
U) 4oOeeOO < U G44D)4
WO 2007/093409 PCT/EP2007/001294
Il
w w C)
1 1 O O 4 LO %D M o-4 4 m 4 o- 0o C ( 4 U U U LO m CD CD < 0D C) CD CD 0D r-I .4 $-M M i M- I | O 0 O 0 I W 0 0 0 0 0 0 0 I
4-3 .4- -W 4iJ - 0 W Q0 I I I I M M I I I I I I I a4 "o O )o r- o om m mm m o ra r- r- r- a- - o
I I I I I i a a o o o o o o o o I 0 oM 0 o o o o o o J
m' m' m' m m 0 0 m' m' m' m z m m a' m a' a' m m' - l l l
4 f
4 f
4 Z Z fl l l l l II f4
f4
f4
f4
f 4
U 0 <
:'3:
O 4 O
(5( U U U U < U M
Ou U U U u U U < U O u u > n A U < D n Du < n n ( ( > (5(5' U (55( 4 5 ( U U U (x D OUOU U 4 U U (5 U >
DI 4 (5 D DD U M D D' U U>
D D D D n U D n D n 5: r D 4
u O O O u 0 u O D < < < 0 u
u : D0 u n n D DDGGDD U U U U U
u < 0 u 0 0 O O z :D 4 : <DOO DD U U U U U 0 0 1D4 4 (5 D D (5(5(5(5(< U UU D ' (5:':':' :' cM
S< U 0 : D r: < 0 0 0 n D n w n < u u 0 0 u n 0 0 0 0 Z D 0 0 n n E
ZD n n u n 0 0 4 4 <: < u 0 D OO Ga4 < < Z5( D 0 U U 0 D U U U H
U 0 0 < 0 D 0 <
U O U U U~ U((( e (5 e (5(5 Z
< 0 < D :: 0 0 n 0 0 0 0 0 u 0 0 0 0 p
n < u 0 u O 0 0 D 0 0 0
(5 u U (5( u :' u (((5( :' 0 (5: 0
< U(5( U U U D 5 n5 U (5(5 U U545 n (5 (5 D U 5 U U 5(5 4
0 < 0 < < ZD < D < < <
< u u u u :D ZD :D n z U ( 4 0 U:':' ( U UU (5 U U5(5( U U (
e (5 o (5 ( (5 4(5(5(5 (5(5 U <5(<(5(5
D U U U U < n D (5(5( U ( 0 U U(5 ( H
U) 4(4 4 4545U U . : : : G U U < G U U 0 Ci C
m I(5 5( i( I (5 I U U i U:':' W m ~((55((5N~ C1 (55(( (5(5 (5 (5 U CN C
Qf Q Q QQ Q5(Q(Q(Q(5(5 (5U Q(5(Q(5(50
o ~ c c~ o o o o oc o o a
WO 2007/093409 PCT/EP2007/001294
a4 a 4J 04 -P CO-) U ) T -i
L m 0 ) 0 0 r- r4i w 1 0 C±1 > I I u C) -i C) I H- la 0) 0 0 0
( m t.0 k. 4- 'D~ 0 0
I X < I Q 1 0 rHA (n) LO 1 -4 r-4 4 0 0 x 0 0 0- 04 04 X4 u X
Z Z 0~ - 0j 0 0) 0 0 0 0 0
M >4 U) > ws x x U) > z z 4- - 1> >I 4-4 - '.
4 w'~~ 0 U) ~ ~ 0 co > 0 a 4 >
3: 3 U) 3: a-4 aH 1 ( f- w w z zI 4 1i U) U) UO
> w U) > < 0 a4' U) a4i~ x U) 0-' 134 a-4 0- 0 04. 0 4 z- z- z
01 z 0 -q 4 C k-0 0 < E- 0 u
>0 a' > 0' 4 -4 Z 0 0O4r U) Q > 14- 0 0
0 U) 0 z >Z
4 4 4 > 0 4~ 0 D rI
14 > 4LI z U)c4n- '-4 '- > > U) 0 > > >
F-I > > H a' w w 0 D 0 4 <- p U) H H H O0.. (' 134 fr4 z 09 0' 09
u z U) z > H < 00( U) U) 0) U) >-. wx 0 0 0
0D D 0 0 u - 04 U ) >4 a:] I 0 -4 C9 U) 4 >4 0a. a.. a.
u U) U) 0 . 0 0 0D 0 +0 0 U) H ) a4 0 j a-. 0
00 v 0 H HE- 0 - U) U) U) 00 U a! <:: z >-I LI z~ 4 00 Z 0D 0 r. 44 U) C9 > > >
1 0< > >4 02 124 z- fl4 Z 0l 0 0 > a 40- > > > 0 0-. 0 H cf '-4 U
u 00 H 0 - 4i. 4 U) 4 Ca 09 0 0 0 '-4 r z :1 U) >-I 4-i H-
00i z- Z 0.4 E-. H z Z z
Q.. a- 0' p p- OH4- 4 44
D )U) 0) 0' Ci 4 H u 0 0D 0D 0D 0 0 CI U) H U)-0 0' 0' 0'
HD 0 ' 1 0 H 04 4-4 0-. I 0 ) 0 04. CL >4 U) >4 :1 U) H- H- H
) D 0D U) U) U) CL. .'i Z a4 i 0 0'
0 00 09u r: 0 (D 04 0-ZO 0' 0' ' Gq 0 4< a 0 Wi- U) Z~ H Z H Z
0 0 W 4 03 04 wi- x 0-. 0-. H4 0 H 0a. U) H0 0 .- xU) 0 w 0 w 0 w 0
PQ >- aj U) zU) (D>-iU) 4U) H z p wz 0 0D U0' 0 4U )C wHz<
>1 0) 0 - - U) Z 034 4 3 ZL>Z X 0 U) X a4 U) -4 (a 10 0 LO 1O 4 4 U40 U ) 4::H C'l<
-H -H * rA - A * l -H *H -I 0Z ) a) w) a) ) a) a) a) 0
z z z z 4J .4J 4J 41 41 4-i -P -P S0 0 0 0 0 0 0 0 0 0 0 0
$-I 44 4-4 4 4 s-I s-4 4
H m 1O0 1 r- OD 01, C) r-4 (.4 m LO1 I 01 10 1O 1O 10 1O '.O '.O i.0 '.0 'l.0 w.
N\ N\ . C\J CN (N N N (N4 (N (N N
WO 2007/093409 PCT/EP2007/001294
a)
c 2 Irv
x xZx x
-1 co Cr. ( a r-1 r-4 r
1 = O) C) 19T ) C) N) N) C) i C) 4 r" C
6 ~ ~ ~ ~ U U) 4a4a ) )
H H > C) 0l
- I 00 m C -I i-i
cr: U I u- u ID u
w w > >) CD > 1 0
a z U) U C
H > > >1 H H H Z
C) U)~ I-I >- 4
O ~z)01Oz)
r:4 U) > 4 z > Q
C D H - E- U) U >C
HH > 04~ FA < Z
> > >> H H
' 0 a w>M - I>I .> :I <En z a > H >
E0 CC. aH H (9 0 o Z a4 C) O 'H
u- 0 F, ' U) U) 4 0 > la4U F4 P > a4 4 > z
0 0 x 14 " x x x x
> F-q u > H H > 0
CD 0. 0.U ).4
01~ ~ ~ 44Z '- > a1 HZ HZ U) H01U) 0 > > 4
a4> >U) HU)> Ci ) 4 0 c1 > > H 0 m x z zU a
4~ ~ p z H
H Z HZ a P a C -~l -~ CH > > H
HM HH
1CD HU) z 0Ci- >)U U)) CD U) U C) C) Z ) 4C Z1 'H> a-4i 4 0Z 4C ~~~~ cu r'H F.~i 4)1 ) C4CC CC>) >- ZH 44- 'H Z 4 )~ H U - i 4 X 44. X O > ) C 4 <4 > z
W0 u .- c-- u-~- HO u0 D 6 uD 4 u r>4 H CYcf W >> W> 04 KC> U HW - U > U U I U H4
Z~~~ H H Of 40Z
CD >->
W > > > > a4 > i- M U>
F4~ ~ ~ ~ x <o z4 F
D4 U)H M X H> >' .4 M W M W 0
4~~~ ~ >' -' <. w >~ w e>4>4
a4) -H *4 r H *H -H a4 -4a H aH 04 >4 a4 H1 cn CD 0 a )4 w a U) >, W aH>, 4 W 4
Schneider 1999). Remarkably, delayed onset of CCL2 blockade also reduced the numbers of
interstitial macrophages being associated with less tubulointerstitial pathology in 1K db/db mice.
Together, these data validate CCL2 as a promising therapeutic target for diabetic nephropathy
and suggest that initiating CCL2 blockade with a Spiegelmer - even at an advanced stage of the
disease - may still be protective.
WO 2007/093409 PCT/EP2007/001294
107
References
The complete bibliographic data of the documents recited herein the disclosure of which is
incorporated by reference is, if not indicated to the contrary, as follows.
Akahoshi T, Wada C, Endo H, Hirota K, Hosaka S, Takagishi K, Kondo H, Kashiwazaki S, Matsushima K (1993). Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. Arthritis Rheum. 36:762
Alam R, York J, Moyars M, Stafford S, Grant JA, Lee J, Forsythe P, Sim T, Ida N (1996). Increased MCP-1, RANTES, and MIP-la in bronchoalveolar lavage fluid of allergic asthmatic patients. Am. J. Respir. Crit. Care Med 153:1398
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990), Basic local alignment search tool. JMol Biol. 215(3):403-10.
Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. Sep 1;25(17):3389-402.
Amann B, Tinzmann R, Angelkort B (2003). ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26:2421
Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, Kretzler M, Strutz F, Mack M, Grone HJ, Onuffer J, Horuk R, Nelson PJ, Schlkndorff D (2002). A chemokine receptor CCR- 1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. 109:251
Anders HJ, Vielhauer V, Schlondorff D (2003). Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 63:401
Aurup H et al. (1994). Nucleic Acids Res 22:20
Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984). Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25:689
Baggiolini M, Dewald B, Moser B (1994). Interleukin-8 and related chemotactic cytokines CXC and CC chemokines. Adv. Immunol. 55:97
Baggiolini M (1998). Chemokines and leukocyte traffic. Nature 392:565
Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K (2000). Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58:684
Banisor I, Leist TP, Kalman B (2005). Involvement of p-chemokines in the development of inflammatory demyelination. J. Neuroinflammation 2:7
Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997). A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640
WO 2007/093409 PCT/EP2007/001294
108
Berkhout TA (1997). JBiol Chem 272:16404
Bohle A, Wehrmann M, Bogenschutz 0, Batz C, Muller CA, Muller GA (1991). The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol. Res. Pract. 187:251
Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF (1997). Impaired monocyte migration and reduced type 1 (Thl) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin. Invest. 100:2552
Boring L, Gosling J, Cleary M, Charo IF (1998). Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894
Boring L, Gosling J, Monteclaro FS, Lusis AJ, Tsou CL, Charo IF (1996). Molecular cloning and functional expression of murine JE (monocyte chemoattractant protein 1) and murine macrophage inflammatory protein lalpha receptors: evidence for two closely linked C-C chemokine receptors on chromosome 9. J. Biol. Chem. 271:7551
Bossink AW, Paemen L, Jansen PM, Hack CE, Thijs LG, Van Damme J (1995). Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. Blood 86:3841
Bower G, Brown DM, Steffes MW, Vernier RL, Mauer SM (1980). Studies of the glomerular mesangium and the juxtaglomerular apparatus in the genetically diabetic mouse. Lab. Invest. 43:333
Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR (1994). Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl Acad. Sci. USA 91:2752
Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH (2007). Monocyte chemoattractant protein-I-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologica 50:471
Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH (2006). Monocyte chemoattractant protein-i promotes the development of diabetic renal injury in streptozotocintreated mice. Kidney Int. 69:73 Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004). Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. Kidney Int. 65:116 Cockwell P, Howie AJ, Adu D, Savage CO (1998). In situ analysis of C-C chemokine mRNA in human glomerulonephritis. Kidney Int. 54:827
Cohen CD, Grone HJ, Gr6ne EF, Nelson PJ, Schl6ndorff D, Kretzler M (2002). Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue. Kidney Int. 61:125
Cummins LL et al. (1995). Nucleic Acids Res 23:2019
Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, Plebani M, Fioretto P (2005). Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 16 Suppl 1:S78
Dawson J, Miltz W, Mir AK, Wiessner C (2003). Targeting monocyte chemoattractant protein-I signalling in disease. Expert Opin. Ther. Targets 7:35
WO 2007/093409 PCT/EP2007/001294
109
De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM (2002). Differential expression of chemokines in inflammatory myopathies. Neurology 58:1779
Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA (2000). Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17:1503
Eaton BE et al. (1995). Chem Biol 2:633
Eaton BE, Gold L, Hicke BJ, Janjic N, Jucker FM, Sebosta DP, Tarasow TM, Willis MC, Zichi DA (1997). Bioorg Med Chem 5:1087
Economou E, Tousoulis D, Katinioti A, Stefanadis C, Trikas A, Pitsavos C, Tentolouris C, Toutouza MG, Toutouzas P (2001). Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. Int. J Cardiol. 80:55
Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A (2002). Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ. Res. 90:1167
Fujinaka H, Yamamoto T, Takeya M, Feng L, Kawasaki K, Yaoita E, Kondo D, Wilson CB, Uchiyama M, Kihara I (1997). Suppression of anti-glomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-i antibody in WKY rats. J. Am. Soc. Nephrol. 8:1174
Furuichi K, Wada T, Iwata Y, Kitagawa K, Kobayashi K-I, Hashimoto H, Ishiwata Y, Tomosugi N, Mukaida N, Matsushima K, Egashira K, Yokoyama H (2003). Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemiareperfusion injury. J. Am. Soc. Nephrol. 14:1066
Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K (1993). The role of macrophages in diabetic glomerulosclerosis. Am. J Kidney Dis. 21:480
Galasso JM, Liu Y, Szaflarski J, Warren JS, Silverstein FS (2000). Monocyte chemoattractant protein-I is a mediator of acute excitotoxic injury in neonatal rat brain. Neuroscience 101:737
Galkina E, Ley K (2006). Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 17:368-377
Gao JL, Kuhns DB, Tiffany HL, McDermott D, Li X, Francke U, Murphy PM (1993). Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J Exp. Med. 177:1421
Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, Murphy PM, Luster AD (1996). Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J. Immunol. 157:5613
Gerard C, Rollins, BJ. Chemokines and disease. Nat. Immunol. 6:1182
Gong X, Gong W, Kuhns DB, Ben-Baruch A, Howard OM, Wang JM (1997). Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J. Biol. Chem. 272:11682
Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TNC, Proudfoot A, Martinez-A C, Dorf M, Bjerke T, Coyle AJ, Gutierrez-Ramos JC (1998). The coordinated action of CC chemokines in
WO 2007/093409 PCT/EP2007/001294
110
the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp. Med 188:157
Gordillo GM, Onat D, Stockinger M, Roy S, Atalay M, Beck FM, Sen CK (2004). A key angiogenic role of moncyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am. J. Physiol. Cell Physiol. 287:C866
Green LS et al. (1995). Chem Biol 2:683
Handel TM, Domaille PJ (1996). Heteronuclear (I H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-I (MCP-1) dimer. Biochemistry 35:6569
Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S (1993). Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin. Immunol. Immunopathol. 69:83
Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie 0, Nose M, Fujita S (2003). Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum. 48:2555
Heath H, Qin S et al. (1997). Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 99:178
Holdsworth SR, Kitching AR, Tipping PG (2000). Chemokines as therapeutic targets in renal disease. Curr. Opin. Nephrol. Hypertens. 9:505
Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM (1997). Release of RANTES, MIP-la, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am. J. Respir. Crit. Care Med 156:1377
Hosaka S et al. (1994). Clin Exp Immunol 97:451
Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM (2001). Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigenspecific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med 193:713
Hulkower K, Brosnan CF, Aquino DA, Cammer W, Kulshrestha S, Guida MP, Rapoport DA, Berman JW (1993). Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J. Immunol. 150:2525
Humbert M, Ying S, Corrigan C, Menz G, Barkans J, Pfister R, Meng Q, Van Damme J, Opdenakker G, Durham SR, Kay AB (1997). Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophagecolony-stimulating factor, and IL-3. Am JRespir Cell Mol Biol 16:1
Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha DR, Ha H (1998). A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 79:33
Iyonaga K, Takeya M, Saita N, Sakamoto 0, Yoshimura T, Ando M, Takahashi K (1994). Monocyte chemoattractant protein-i in idiopathic pulmonary fibrosis and other interstitial lung diseases. Hum. Pathol. 25:455
Johrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander H, Holtl L, Bartsch G, Greil R, Thurnher M (2005). Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 11:2459
WO 2007/093409 PCT/EP2007/001294
111
Jolicoeur C, Lemay A, Akoum A (2001). Comparative effect of danazol and a GnRH agonist on monocyte chemotactic protein-i expression by endometriotic cells. Am. J. Reprod Immunol. 45:86
Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong 0, Hsuan JJ, Williams TJ. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp. Med. 179:881
Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S (2001). Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-la, MIP-1p, and eotaxin) in patients with atopic dermatitis. Arch. Dermatol. Res. 293:350
Kawasaki AM et al. (1993). J Med Chem 36:831
Kennedy KJ, Strieter RM, Kunkel SL, Lukacs NW, Karpus WJ (1998). Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-la and monocyte chemotactic protein-1. J. Neuroimmunol. 91:98
Kim JS, Gautam SC, Chopp M, Zaloga C, Jones ML, Ward PA, Welch KM (1995). Expression of monocyte chemoattractant protein-i and macrophage inflammatory protein-i after focal cerebral ischemia in the rat. J. Neuroimmunol. 56:127
Kitamoto S, Egashira K (2003). Anti-monocyte chemoattractant protein-i gene therapy for cardiovascular diseases. Expert Rev. Cardiovasc. Ther. 1:393
Kleinhans M, Tun-Kyi A, Gilliet M, Kadin ME, Dunmer R, Burg G, and Nestle FO (2003). Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood 101:1487
Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM (1992). Enhanced production of monocyte chemoattractant protein-I in rheumatoid arthritis. J. Clin. Invest. 90:772
Kouno J, Nagai H, Nagahata T, Onda M, Yamaguchi H, Adachi K, Takahashi H, Teramoto A, and Emi M (2004). Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth. JNeurooncol 70:301
Kurihara T, Warr G, Loy J, Bravo R (1997). Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med 186:1757
Kusser W (2000). JBiotechnol 74:27-38
Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies 0, Ley K, Maeda N (1997). Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl Acad. Sci. US A 94:12053
Lesnik EA et al. (1993). Biochemistry 32:7832
Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TNC, Salant DJ, Gutierrez-Ramos JC (1997). RANTES and monocyte chemoattractant protein-I (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med 185:1371
Lu BB, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ (1998). Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein-I deficient mice. J. Exp. Med 187:601
WO 2007/093409 PCT/EP2007/001294
112
Lubkowski J, Bujacz G, Boque L, Domaille PJ, Handel TM, WIodawer A (1997). The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat Struct Biol 4:64
Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AE, Plachy J, Bruhl H, Frink M, Anders HJ, Vielhauer V, Pfirstinger J, Stangassinger M, Schlondorff D (2001). Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166:4697
Martinelli R, Sabroe I, LaRosa G, Williams TJ, Pease JE. The CC chemokine eotaxin (CCL1 1) is a partial agonist of CC chemokine receptor 2b. J Biol Chem 276:42957
Matsushima K, Morishita K, Yoshimura T, Lavu S, Kobayashi Y, Lew W, Appella E, Kung HF, Leonard EJ, Oppenheim JJ (1989). Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med 167:1883
McGinnis S, Madden TL (2004). BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res. 32(Web Server issue):W20-5.
Miller MD, Krangel MS (1992). Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit. Rev. Immunol. 12:17
Miller LE et al. (1993). JPhysiol 469:213
Mora C, Navarro JF (2005). The role of inflammation as a pathogenic factor in the development of renal disease in diabetes. Curr. Diab. Rep. 5:399
Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M, Ito S (2003). Association of monocyte chemoattractant protein-I with renal tubular damage in diabetic nephropathy. J. Diabetes Complications 17:11
Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145
Nakamura H, Weiss ST, Israel E, Luster AD, Drazen JM, Lilly CM (1999). Eotaxin and impaired lung function in asthma. Am JRespir Crit Care Med 160:1952
Nakazawa T, Hisatomi T, Nakazawa C, Noda K, Maruyama K, She H, Matsubara A, Miyahara S, Nakao S, Yin Y, Benowitz L, Hafezi-Moghadam A, Miller JW (2007). Monocyte chemoattractant protein 1 mediated retinal detachment-induced photoreceptor apoptosis. Proc Natl. Acad. Sci. USA 104:2425
Navarro JF, Mora C, Maca M, Garca J (2003). Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am. J. Kidney Dis. 42:53
Myers SJ, Wong LM, Charo IF (1995). Signal transduction and ligand specificity of the human monocyte chemoattractant protein-1 receptor in transfected embryonic kidney cells. J Biol. Chem. 270:5786
Needleman & Wunsch (1970), A general method applicable to the search for similarities in the amino acid sequence of two proteins. JMol Biol. 48(3):443-53.
Nelken NA, Coughlin SR, Gordon D, Wilcox JN (1991). Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin. Invest. 88:1121
WO 2007/093409 PCT/EP2007/001294
113
Neote K, DiGregorio D, Mak JY, Horuk R, Schall TJ (1993). Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72:415
Ninichuk V, Gross 0, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, de Lema GP, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R, Weber M, Krombach F, Schlondorff D, Anders HJ (2005). Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am. Soc. Nephrol. 16:977
Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K (1997). The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. 182:106
Okuno T, Andoh A, Bamba S, Araki Y, Fujiyama Y, Fujiyama M, Bamba T (2002). Interleukin1p and tumor necrosis factor-a induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand. J. Gastroenterol. 37:317
Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K (1991). Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu. Rev. Immunol. 9:617
Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schl6ndorff D, Anders HJ (2006). Tolllike receptor-7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol. 17:141
Pearson & Lipman (1988), Improved tools for biological sequence comparison. Proc. Nat'l. Acad. Sci. USA 85: 2444
Perez de Lema G, Maier H, Franz TJ, Escribese M, Chilla mS, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schl6ndorff D, Luckow B (2005). Chemokine receptor CCR2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am. Soc. Nephrol. 16:3592
Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schl6ndorff D. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am. Soc. Nephrol. 12:1369
Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR (1996a). Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J. Clin. Invest. 97:604
Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, Newman W, Gerard C, Mackay CR (1996b). Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J. Exp. Med. 183:2437
Power CA, Meyer A, Nemeth K, Bacon KB, Hoogewerf AJ, Proudfoot AE, Wells TN (1995). Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J. Biol. Chem. 270:19495
Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD (2004). Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am. J. Physiol. Renal Physiol. 286:F590
Qin S, LaRosa G, Campbell JJ, Smith-Heath H, Kassam N, Shi X, Zeng L, Buthcher EC, Mackay CR (1996). Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. Eur. J. Immunol. 26:640
Ransohoff RM et al. (1993). FASEB J7:592
WO 2007/093409 PCT/EP2007/001294
114
Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF (1996). Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP- 1p, and MIP-la. J. Biol. Chem. 271:17161
Ritz E, Rychlik I, Locatelli F, Halimi S (1999). End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 34:795-808
Rollins BJ, Stier P, Ernst T, Wong GG (1989). The human homolog of the JE gene encodes a monocyte secretory protein. Mol. Cell Biol. 9:4687
Rollins BJ (1996). Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today 2:198
Rovin BH, Rumancik M, Tan L, Dickerson J (1994). Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab. Invest. 71:536
Ruffing N, Sullivan N, et al. (1998). CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol 189:160
Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Keinman HK, Oppenheim JJ, Murphy WJ (2000). Human endothelial cells express CCR2 and respond to MCP- 1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34
Samson M, Labbe 0, Mollereau C, Vassart G, Parmentier M (1996). Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35:3362
Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl RA (1999). Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int. 56:135
Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelly VR, Relle M, Galle PR (2005). Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16:3264
Schwartz CJ, Valente AJ, Sprague EA (1993). A modern view of atherogenesis. Am. J. Cardiol. 71:9B
Segerer S, Nelson PJ, Schlondorff D (2000). Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am. Soc. Nephrol. 11:152
Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M (2004). Anti-monocyte chemoattractant protein-I gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 43:1121
Smith & Waterman (198 1), Adv. Appl. Math. 2: 482
Springer TA (1995). Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev.Physiol. 57:827
Steinman L (2004). Immune therapy for autoimmune diseases. Science 305:212
Svensson M, Sundkvist G, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Henricsson M, Nystrom L, Torffvit 0, Waernbaum I, Ostman J, Eriksson JW (2003). Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: Results from the
WO 2007/093409 PCT/EP2007/001294
115
nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26:2903
Takebayashi K, Matsumoto S, Aso Y, Inukai T (2006). Association between circulating monocyte chemoattractant protein-I and urinary albumin excretion in nonobese Type 2 diabetic patients. J. Diabetes Complications 20:98
Takeya M, Yoshimura T, Leonard EJ, Takahashi K (1993). Detection of monocyte chemoattractant protein-i in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum. Pathol. 24:534
Tang WW, Qi M, Warren JS (1996). Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int. 50:665
Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, Koizumi M, Funabiki K, Horikoshi S, Shirato I, Tomino Y (2002). Urinary levels of monocyte chemoattractant protein-I (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16:1
Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR (1999). Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRLFas(lpr) mice. J. Exp. Med. 190:1813
Tuaillon N, Shen de F, Berger RB, Lu B, Rollins BJ, Chan CC (2002). MCP-1 expression in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 43:1493
Tuttle KR (2005). Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J. Am. Soc. Nephrol. 16:1537
Uguccioni M, Mackay CR et al. (1997). High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 100:1137
United States Renal Data System (2004). Annual data report: Incidence and prevalence 2004. Am. J. Kidney Dis. 45:S77
Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R (2003). Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 63:209
Van Riper G, Siciliano S, Fischer PA, Meurer R, Springer MS, Rosen H (1993). Characterization and species distribution of high affinity GTP-coupled receptors for human rantes and monocyte chemoattractant protein 1. J Exp. Med. 177:851
Venkatesan N et al. (2003). Curr Med Chem 10:1973
Vestergaard C, Just H, Baumgartner Nielsen J, Thestrup-Pedersen K, Deleuran M (2004). Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta Derm. Venereol. 84:353
Viedt C, Orth SR (2002). Monocyte chemoattractant protein-i (MCP-1) in the kidney: does it more than simply attract monocytes? Nephrol. Dial. Transplant. 17:2043
Wada T, Furuichi K, Segada-Takaeda C, Ahimizu M, Sakai N, Takeda SI, Takasawa K, Kida H, Kobayashi KI, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H (1999). MIP-la and MCP1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int. 56:995
WO 2007/093409 PCT/EP2007/001294
116
Wada T, Yokoyama H, Matsushima K, Kobayashi KI (2001). Chemokines in renal diseases. Int. Immunopharmacol. 1:637
Wada T, Yokoyama H, Furuichi K, Kobayashi KI, Harada K, Naruto M, Su SB, Akiyama M, Mukaida N, Matsushima K (1996). Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J. 10:1418
Wang X, Yue TL, Barone FC, Feuerstein GZ (1995). Monocyte chemoattractant protein-1 messenger RNA expression in rat ischemic cortex. Stroke 26:661
Wenzel U, Schneider A, Valente AJ, Abboud HE, Thaiss F, Helmchen UM, Stahl RA (1997). Monocyte chemoattractant protein-i mediates monocyte/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int. 51:770
Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z (2002). Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-i in human-cultured mesangial cells. J. Biol. Chem. 277:20309
Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR, Williams TJ, Kay AB (1997). Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 27:3507
Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, Kay AB (1999). Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. JImmunol 163:6321
Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D (1991). Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. NatlAcad. Sci. USA 88:5252
Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ (1989). Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutininstimulated human blood mononuclear leukocytes. J. Immunol. 142:1956
Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, Okada S, Wada J, Nagase R, Ogawa D, Shikata Y, Makino H (2005). Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am. Soc. Nephrol. 16:3326
Zimmet P, Alberti KG, Shaw J (2001). Global and societal implications of the diabetes epidemic. Nature 414:782
The features of the present invention disclosed in the specification, the claims and/or the
drawings may both separately and in any combination thereof be material for realizing the
invention in various forms thereof.
WO 2007/093409 PCT/EP2007/001294
117
Claims
1. A nucleic acid, preferably binding to MCP-1, selected from the group comprising type
1 A nucleic acids, type 1 B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic
acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to
115.
2. The nucleic acid according to claim 1, whereby the type 1A nucleic acid comprises in 5'
>3' direction a first stretch Box BlA, a second stretch Box B2, a third stretch Box B3, a fourth
stretch Box B4, a fifth stretch Box B5, a sixth stretch Box B6 and a seventh stretch Box BlB,
whereby
the first stretch Box BlA and the seventh stretch Box BIB optionally hybridize with each
other, whereby upon hybridization a double-stranded structure is formed,
the first stretch Box BlA comprises a nucleotide sequence of AGCRUG,
the second stretch Box B2 comprises a nucleotide sequence of CCCGGW,
the third stretch Box B3 comprises a nucleotide sequence of GUR,
the fourth stretch Box B4 comprises a nucleotide sequence of RYA,
the fifth stretch Box B5 comprises a nucleotide sequence of GGGGGRCGCGAYC
the sixth stretch Box B6 comprises a nucleotide sequence of UGCAAUAAUG or
URYAWUUG, and
the seventh stretch Box BIB comprises a nucleotide sequence of CRYGCU.
3. The nucleic acid according to claim 2, whereby
WO 2007/093409 PCT/EP2007/001294
118
the first stretch Box BlA comprises a nucleotide sequence of AGCGUG.
4. The nucleic acid according to claims 2 or 3, whereby
the second stretch Box B2 comprises a nucleotide sequence of CCCGGU.
5. The nucleic acid according to any of claims 2 to 4, whereby
the third stretch Box B3 comprises a nucleotide sequence of GUG.
6. The nucleic acid according to any of claims 2 to 5, whereby
the fourth stretch Box B4 comprises a nucleotide sequence of GUA.
7. The nucleic acid according to any of claims 2 to 6, whereby
the fifth stretch Box B5 comprises a nucleotide sequence of GGGGGGCGCGACC.
8. The nucleic acid according to any of claims 2 to 7, whereby
the sixth stretch Box B6 comprises a nucleotide sequence of UACAUUUG.
9. The nucleic acid according to any of claims 2 to 8, whereby
the seventh stretch Box B 1 B comprises a nucleotide sequence of CACGCU.
10. The nucleic acid according to any of claims 2 to 9, whereby the nucleic acid comprises a
nucleic acid sequence according to SEQ.ID. No 21.
11. The nucleic acid according to claim 1, whereby the type lB nucleic acid comprises in 5'
>3' direction a first stretch Box BlA, a second stretch Box B2, a third stretch Box B3, a fourth
stretch Box B4, a fifth stretch Box B5, a sixth stretch Box B6 and a seventh stretch Box BIB,
whereby
WO 2007/093409 PCT/EP2007/001294
119
the first stretch Box BlA and the seventh stretch Box BIB optionally hybridize with each
other, whereby upon hybridization a double-stranded structure is formed,
the first stretch Box B 1 A comprises a nucleotide sequence of AGYRUG,
the second stretch Box B2 comprises a nucleotide sequence of CCAGCU or CCAGY,
the third stretch Box B3 comprises a nucleotide sequence of GUG,
the fourth stretch Box B4 comprises a nucleotide sequence of AUG,
the fifth stretch Box B5 comprises a nucleotide sequence of GGGGGGCGCGACC
the sixth stretch Box B6 comprises a nucleotide sequence of CAUUUUA or CAUUUA,
and
the seventh stretch Box B 1 B comprises a nucleotide sequence of CAYRCU.
12. The nucleic acid according to claim 11, whereby
the first stretch Box BlA comprises a nucleotide sequence of AGCGUG.
13. The nucleic acid according to claims 11 or 12, whereby
the second stretch Box B2 comprises a nucleotide sequence of CCAGU.
14. The nucleic acid according to any of claims 11 to 13, whereby
the sixth stretch Box B6 comprises a nucleotide sequence of CAUUUUA.
15. The nucleic acid according to any of claims 11 to 14, whereby
the seventh stretch Box BIB comprises a nucleotide sequence of CACGCU.
WO 2007/093409 PCT/EP2007/001294
120
16. The nucleic acid according to any of claims 11 to 15, whereby the nucleic acid comprises
a nucleic acid sequence according to SEQ.ID.No 28 and SEQ.ID.No 27.
17. The nucleic acid according to claim 1, whereby the type 2 nucleic acid comprises in 5'
>3' direction a first stretch Box BlA, a second stretch Box B2, and a third stretch Box BIB,
whereby
the first stretch Box B1A and the third stretch Box B1B optionally hybridize with each
other, whereby upon hybridization a double-stranded structure is formed,
the first stretch Box BlA comprises a nucleotide sequence selected from the group
comprising ACGCA, CGCA and GCA,
the second stretch Box B2 comprises a nucleotide sequence of
CSUCCCUCACCGGUGCAAGUGAAGCCGYGGCUC, and
the third stretch Box B1B comprises a nucleotide sequence selected from the group
comprising UGCGU, UGCG and UGC.
18. The nucleic acid according to claim 17, whereby
the second stretch Box B2 comprises a nucleotide sequence of
CGUCCCUCACCGGUGCAAGUGAAGCCGUGGCUC.
19. The nucleic acid according to any of claims 17 to 18, whereby
a) the first stretch Box BlA comprises a nucleotide sequence of ACGCA,
and
the third stretch Box B 1 B comprises a nucleotide sequence of UGCGU; or
b) the first stretch Box B 1 A comprises a nucleotide sequence of CGCA,
and
the third stretch Box BIB comprises a nucleotide sequence of UGCG; or
WO 2007/093409 PCT/EP2007/001294
121
c) the first stretch Box B 1 A comprises a nucleotide sequence of GCA,
and
the third stretch Box BIB comprises a nucleotide sequence of UGC or UGCG.
20. The nucleic acid according to any of claims 17 to 19, whereby
the first stretch Box B 1 A comprises a nucleotide sequence of GCA.
21. The nucleic acid according to any of claims 17 to 20 and preferably claim 20, whereby
the third stretch Box B 1 B comprises a nucleotide sequence of UGCG.
22. The nucleic acid according to any of claims 17 to 21, whereby the nucleic acid comprises
a nucleic acid sequence according to SEQ.ID.No 37, SEQ.ID.No 116, SEQ.ID.No 117 and
SEQ.ID.No 278.
23. The nucleic acid according to claim 1, whereby the type 3 nucleic acid comprises in 5'
>3' direction a first stretch Box BlA, a second stretch Box B2A, a third stretch Box B3, a fourth
stretch Box B2B, a fifth stretch Box B4, a sixth stretch Box B5A, a seventh stretch Box B6, an
eighth stretch Box B5B and a ninth stretch Box BIB, whereby
the first stretch Box B1A and the ninth stretch Box B1B optionally hybridize with each
other, whereby upon hybridization a double-stranded structure is formed,
the second stretch Box B2A and the fourth Box B2B optionally hybridize with each
other, whereby upon hybridization a double-stranded structure is formed,
the sixth stretch Box B5A and the eighth Box B5B optionally hybridize with each other,
whereby upon hybridization a double-stranded structure is formed,
the first stretch Box BlA comprises a nucleotide sequence which is selected from the
group comprising GURCUGC, GKSYGC, KBBSC and BNGC,
WO 2007/093409 PCT/EP2007/001294
122
the second stretch Box B2A comprises a nucleotide sequence of GKMGU,
the third stretch Box B3 comprises a nucleotide sequence of KRRAR,
the fourth stretch Box B2B comprises a nucleotide sequence of ACKMC,
the fifth stretch Box B4 comprises a nucleotide sequence selected from the group
comprising CURYGA, CUWAUGA, CWRMGACW and UGCCAGUG,
the sixth stretch Box B5A comprises a nucleotide sequence selected from the group
comprising GGY and CWGC,
the seventh stretch Box B6 comprises a nucleotide sequence selected from the group
comprising YAGA, CKAAU and CCUUUAU,
the eighth stretch Box B5B comprises a nucleotide sequence selected from the group
comprising GCYR and GCWG, and
the ninth stretch Box B 1 B comprises a nucleotide sequence selected from the groups
comprising GCAGCAC, GCRSMC, GSVVM and GCNV.
24. The nucleic acid according to claim 23, whereby
the third stretch Box B3 comprises a nucleotide sequence of GAGAA or UAAAA
25. The nucleic acid according to claims 23 or 24, whereby
the fifth stretch Box B4 comprises a nucleotide sequence of CAGCGACU or
CAACGACU.
26. The nucleic acid according to any of claims 23 to 25, whereby
the fifth stretch Box B4 comprises a nucleotide sequence of CAGCGACU and Box B3
comprises a nucleotide sequence of UAAAA.
WO 2007/093409 PCT/EP2007/001294
123
27. The nucleic acid according to any of claims 23 to 25, whereby
the fifth stretch Box B4 comprises a nucleotide sequence of CAACGACU and the third
stretch Box B3 comprises a nucleotide sequence of GAGAA.
28. The nucleic acid according to any of claims 23 to 27, whereby
the seventh stretch Box B6 comprises a nucleotide sequence of UAGA.
29. The nucleic acid according to any of claims 23 to 28, whereby
a) the first stretch Box B 1 A comprises a nucleotide sequence of GURCUGC,
and
the ninth stretch Box BIB comprises a nucleotide sequence of GCAGCAC; or
b) the first stretch Box BlA comprises a nucleotide sequence of GKSYGC,
and
the ninth stretch Box BIB comprises a nucleotide sequence of GCRSMC; or
c) the first stretch Box BlA comprises a nucleotide sequence of KBBSC,
and
the ninth stretch Box B 1 B comprises a nucleotide sequence of GSVVM; or
d) the first stretch Box BlA comprises a nucleotide sequence of BNGC,
and
the ninth stretch Box B 1 B comprises a nucleotide sequence of GCNV.
30. The nucleic acid according to claim 29, whereby
a) the first stretch Box BlA comprises a nucleotide sequence of GUGCUGC,
and
the ninth stretch Box BIB comprises a nucleotide sequence of GCAGCAC; or
WO 2007/093409 PCT/EP2007/001294
124
b) the first stretch Box B 1 A comprises a nucleotide sequence of GUGCGC,
and
the ninth stretch Box BIB comprises a nucleotide sequence of GCGCAC; or
c) the first stretch Box BlA comprises a nucleotide sequence of KKSSC,
and
the ninth stretch Box B 1 B comprises a nucleotide sequence of GSSMM; or
d) the first stretch Box BlA comprises a nucleotide sequence of SNGC,
and
the ninth stretch Box B 1 B comprises a nucleotide sequence of GCNS.
31. The nucleic acid according to claim 30, whereby
the first stretch Box BlA comprises a nucleotide sequence of GGGC,
and
the ninth stretch Box B 1 B comprises a nucleotide sequence of GCCC.
32. The nucleic acid according to any of claims 23 to 31, whereby the second stretch Box
B2A comprises a nucleotide sequence of GKMGU and the fourth stretch Box B2B comprises a
nucleotide sequence of ACKMC.
33. The nucleic acid according to claim 32, whereby the second stretch Box B2A comprises a
nucleotide sequence of GUAGU and the fourth stretch Box B2B comprises a nucleotide
sequence of ACUAC.
34. The nucleic acid according to any of claims 23 to 33, whereby
a) the sixth stretch Box B5A comprises a nucleotide sequence of GGY,
and
the eighth stretch Box B5B comprises a nucleotide sequence of GCYR; or
b) the sixth stretch Box B5A comprises a nucleotide sequence of CWGC,
and
WO 2007/093409 PCT/EP2007/001294
125
the eighth stretch Box B5B comprises a nucleotide sequence of GCWG.
35. The nucleic acid according to claim 34, whereby
the sixth stretch Box B5A comprises a nucleotide sequence of GGC,
and
the eighth stretch Box B5B comprises a nucleotide sequence of GCCG.
36. The nucleic acid according to any of claims 23 to 35, preferably 34 to 35, whereby the
sixth stretch Box B5A hybridizes with the nucleotides GCY of the eighth stretch Box B5B.
37. The nucleic acid according to any of claims 23 to 26 and 28 to 36, whereby the nucleic
acid comprises a nucleic acid sequence according to SEQ.ID.No 56.
38. The nucleic acid according to any of claims 23 to 25 and 27 to 36 , whereby the nucleic
acid comprises a nucleic acid sequence selected from the group comprising the nucleic acid
sequences according to SEQ.ID.No 57 to 61, SEQ.ID.No 67 to 71 and SEQ.ID.No 73.
39. The nucleic acid according to claim 1, whereby the type 4 nucleic acid comprises in 5'
>3' direction a first stretch Box BlA, a second stretch Box B2, a third stretch Box BIB whereby
the first stretch Box B 1 A and the third stretch Box BiB optionally hybridize with each
other, whereby upon hybridization a double-stranded structure is formed,
the first stretch Box B1A comprises a nucleotide sequence selected from the group
comprising AGCGUGDU, GCGCGAG, CSKSUU, GUGUU, and UGUU;
the second stretch Box B2 comprises a nucleotide sequence selected from the group
comprising AGNDRDGBKGGURGYARGUAAAG,
AGGUGGGUGGUAGUAAGUAAAG and CAGGUGGGUGGUAGAAUGUAAAGA,
and
WO 2007/093409 PCT/EP2007/001294
126
the third stretch Box BIB comprises a nucleotide sequence selected from the group
comprising GNCASGCU, CUCGCGUC, GRSMSG, GRCAC, and GGCA.
40. The nucleic acid according to claim 39, whereby
a) the first stretch Box BlA comprises a nucleotide sequence of GUGUU,
and
the third stretch Box BIB comprises a nucleotide sequence of GRCAC;
b) the first stretch Box B 1 A comprises a nucleotide sequence of GCGCGAG,
and
the third stretch Box B 1 B comprises a nucleotide sequence of CUCGCGUC; or
c) the first stretch Box BlA comprises a nucleotide sequence of CSKSUU,
and
the third stretch Box B1B comprises a nucleotide sequence of GRSMSG, or
d) the first stretch Box B 1 A comprises a nucleotide sequence of UGUU,
and
the third stretch Box B 1 B comprises a nucleotide sequence of GGCA, or
e) the first stretch Box BlA comprises a nucleotide sequence of AGCGUGDU,
and
the third stretch Box B 1 B comprises a nucleotide sequence of GNCASGCU.
41. The nucleic acid according to claim 40, whereby the first stretch Box B1A comprises a
nucleotide sequence of CSKSUU and the third stretch Box BIB comprises a nucleotide sequence
of GRSMSG.
42. The nucleic acid according to claims 41, whereby the first stretch Box B1A comprises a
nucleotide sequence of CCGCUU and the third stretch Box B1B comprises a nucleotide
sequence of GGGCGG.
43. The nucleic acid according to any of claims 39 to 42, whereby
WO 2007/093409 PCT/EP2007/001294
127
the second stretch Box B2 comprises a nucleotide sequence of
AGGUGGGUGGUAGUAAGUAAAG.
44. The nucleic acid according to any of claims 39 to 43, whereby the nucleic acid comprises
a nucleic acid sequence according to SEQ.ID.No 80.
45. The nucleic acid according to any of claims 1 to 44, whereby the nucleic acid is capable
of binding a chemokine, whereby the chemokine is selected from the group comprising eotaxin,
MCP-1, MCP-2 and MCP-3.
46. The nucleic acid according to any of claims 1 to 45, whereby the nucleic acid is capable
of binding a chemokine, whereby the chemokine is selected from the group comprising human
eotaxin, human MCP-1, human MCP-2 and human MCP-3.
47. The nucleic acid according to any of claims 1 to 46, whereby the nucleic acid is capable
of binding MCP-1, whereby MCP-1 is preferably selected from the group comprising monkey
MCP- 1, horse MCP- 1, rabbit MCP- 1, bovine MCP- 1, canine MCP- 1, porcine MCP- 1 and human
MCP-1.
48. The nucleic acid according to any of claims 1 to 47, whereby the nucleic acid is capable
of binding human MCP-1.
49. The nucleic acid according to any of claims 1 to 48, preferably claim 48, whereby the
MCP- 1 has an amino acid sequence according to SEQ ID No. 1.
50. A nucleic acid, preferably binding to murine MCP-1, whereby the nucleic acid comprises
a nucleic acid sequence according to SEQ.ID.No. 122, SEQ.ID.No. 253 and SEQ.ID.No. 254.
51. A nucleic acid, preferably binding to murine MCP-1, whereby the nucleic acid comprises
a nucleic acid sequence according to SEQ.ID.No. 127.
52. The nucleic acid according to claim 50 or 51, whereby the murine MCP-1 comprises an
amino acid sequence according to SEQ ID No. 2.
WO 2007/093409 PCT/EP2007/001294
128
53. The nucleic acid according to any of claims 1 to 52, wherein the nucleic acid comprises a
modification, whereby the modification is preferably a high molecular weight moiety and/or
whereby the modification preferably allows to modify the characteristics of the nucleic acid
according to any of claims 1 to 52 in terms of residence time in the animal or human body,
preferably the human body.
54. The nucleic acid according to claim 53, whereby the modification is selected from the
group comprising a HES moiety and a PEG moiety.
55. The nucleic acid according to claim 54, whereby the modification is a PEG moiety
consisting of a straight or branched PEG, whereby the molecular weight of the PEG moiety is
preferably from about 20 to 120 kD, more preferably from about 30 to 80 kD and most
preferably about 40 kD.
56. The nucleic acid according to claim 54, whereby the modification is a HES moiety,
whereby preferably the molecular weight of the HES moiety is from about 10 to 130 kD, more
preferably from about 30 to 130 kD and most preferably about 100 kD.
57. The nucleic acid according to any of claims of 53 to 56, whereby the modification is
coupled to the nucleic acid via a linker.
58. The nucleic acid according to any of claims of 53 to 57, whereby the modification is
coupled to the nucleic acid at its 5'-terminal nucleotide and/or its 3'-terminal nucleotide and/or
to a nucleotide of the nucleic acid between the 5'-terminal nucleotide and the 3'-terminal
nucleotide.
59. The nucleic acid according to any of claims 1 to 58, whereby the nucleotides of or the
nucleotides forming the nucleic acid are L-nucleotides.
60. The nucleic acid according to any of claims 1 to 59, whereby the nucleic acid is an L
nucleic acid.
61. The nucleic acid according to any of claims 1 to 59, whereby the moiety of the nucleic
acid capable of binding MCP- 1 consists of L-nucleotides.
WO 2007/093409 PCT/EP2007/001294
129
62. A pharmaceutical composition comprising a nucleic acid according to any of claims 1 to
61 and optionally a further constituent, whereby the further constituent is selected from the group
comprising pharmaceutically acceptable excipients, pharmaceutically acceptable carriers and
pharmaceutically active agents.
63. The pharmaceutical composition according to claim 62, whereby the pharmaceutical
composition comprises a nucleic acid according to any of claims 1 to 61 and a pharmaceutically
acceptable carrier.
64. Use of a nucleic acid according to any of claims 1 to 61 for the manufacture of a
medicament.
65. Use according to claim 64, whereby the medicament is for use in human medicine or for
use in veterinary medicine.
66. Use of a nucleic acid according to any of claims 1 to 61 for the manufacture of a
diagnostic means.
67. Use according to claim 64 or 65, whereby the medicament is for the treatment and/or
prevention of a disease or disorder selected from the group comprising inflammatory diseases,
autoimmune diseases, autoimmune encephalomyelitis, stroke, acute and chronic multiple
sclerosis, chronic inflammation, rheumatoid arthritis, renal diseases, restenosis, restenosis after
angioplasty, acute and chronic allergic reactions, primary and secondary immunologic or allergic